New approaches to the prevention and treatment of severe S. aureus infections

Drugs of Today

Volumn 36, Issue 8, 2000, Pages 529-539

  Xiong, Y Q ^a   Yeaman, M R ^a   Bayer, A S ^a  

^a Research and Education Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCLOXACILLIN; LINEZOLID; METICILLIN; NAFCILLIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; STAPHYPAN; SULTAMICILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL METABOLISM; CLINICAL TRIAL; HUMAN; INFECTION PREVENTION; NONHUMAN; PENICILLIN RESISTANCE; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

EID: 0033776746     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.8.591834     Document Type: Review

References (78)

1. Staphylococcus aureus: A well-armed pathogen
2. Staphylococcus aureus
3. Staphylococcus aureus infections
4. Antimicrobial resistance of Staphylococcus aureus: Genetic basis
5. Emerging resistance to fluoroquinolones in staphylococci: An alert
6. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors
7. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children
8. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
9. Methicillin-resistant strains of Staphylococcus aureus: Presence of identical additional penicillin-binding proteins in all strains examined
10. Occurrence of a β-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci
11. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: Association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination
12. femA, Which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains
13. Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus
14. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus
15. New mechanism for methicillin resistance in Staphylococcus aureus: Clinical isolates that lack the PBP2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity
16. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
17. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
18. Quinupristin/dalfopristin: A review of its activity in experimental animal models of infection
19. Research and development of antibacterial agents
20. Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis EPK1
21. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristinquinupristin against Staphylococcus aureus and Staphylococcus epidermidis
22. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
23. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus
24. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin
25. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge
26. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A
27. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats
28. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model
29. Protection against endocarditis due to Staphylococcus epidermidis by immunization with capsular polysaccharide/adhesin
30. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen
31. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus
32. Autocrine regulation of toxin synthesis by Staphylococcus aureus
33. Translation of RNAI-II, the Staphylococcus aureus agr regulatory RNA molecule, can be activated by a 3'-end deletion
34. Activation and inhibition of the staphylococcal AGR system
35. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death
36. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis
37. Collagen binding of Staphylococcus aureus is a virulence factor in experimental endocarditis
38. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus
39. Capsular polysaccharides of Staphylococcus aureus
40. Prevention of Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis
41. Vaccination for prevention of CAPD associated staphylococcal infection: Results of a prospective multicentre clinical trial
42. Lack of reproducibility of macrodilution MBCs for Staphylococcus aureus
43. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: Influence and significance of technical factors
44. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bactericidal endocarditis
45. β-Lactams: Mode of action and mechanisms of bacterial resistance
46. Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections
47. Comparison of methicillin, nafcillin, and oxacillin in therapy of Staphylococcus aureus endocarditis in rabbits
48. Unsuccessful treatment of staphylococcal endocarditis with cefazolin
49. Persistent bacteremia in staphylococcal endocarditis
50. β-Lactam-β-lactamase-inhibitor combinations are active in experimental endocarditis caused by β-lactamase-producing oxacillin-resistant staphylococci
51. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by β-lactamase hyperproducing Staphylococcus aureus
52. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: Efficacy of ampicillin-sulbactam
53. Staphylococcus aureus and vancomycin: The sequel
54. Methicillin-resistance in staphylococci: Molecular and biochemical basis and clinical implications
55. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
56. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
57. The effects of vancomycin and β-lactam antibiotics on vancomycin-resistant Staphylococcus aureus
58. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly
59. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains
60. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus
61. In vivo antibiotic synergism: Contribution of animal models
62. Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States
63. The use of rifampin in staphylococcal infections: A review
64. Erythromycin, lincomycin, and clindamycin
65. Antibiotic entry into human polymorphonuclear leukocytes
66. Trimethoprim-sulfamethoxazole for bacterial meningitis
67. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis
68. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus
69. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus
70. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
71. Occurrence and function of D-amino acid-containing peptides and proteins: Antimicrobial peptides
72. Animal antimicrobial peptides: An overview
73. Defensins
74. The role of platelets in antimicrobial host defense
75. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action
76. Phenotypic resistance to thrombin-induced platelet microbicidal protein in vitro is correlated with enhanced virulence in experimental endocarditis due to Staphylococcus aureus
77. In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis
78. Antimicrobial peptides prevent colonization of intravenous catheters